Drug Profile
pWRG/HTN-M(co)/pWRG/PUUV-M(s2)
Alternative Names: Hantaan virus/puumala virus DNA vaccine; Hantaan/puumala virus DNA vaccine; Hantaan/puumala virus vaccine; HTNV/PUU DNA vaccine; HTNV/PUUV DNA vaccine; Puumala/hantaan virus DNA vaccine; pWRG/HTN-M(co)/pWRG/PUU-M(s2); pWRG/HTN-M(x)/pWRG/PUU-M(s2); pWRG/HTN-M(x)/pWRG/PUUV-M(s2)Latest Information Update: 31 Oct 2018
Price :
$50
*
At a glance
- Originator Ichor Medical Systems; United States Army Medical Research and Materiel Command
- Class DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Viral haemorrhagic fevers
Most Recent Events
- 31 Oct 2018 U.S. Army Medical Research and Materiel Command plans a phase I trial for Viral haemorrhagic fevers (Prevention; caused by hantaan and puumala virus) in May 2019 (NCT03718130)
- 26 Dec 2016 Phase-II development is ongoing in USA (NCT02116205)
- 01 Aug 2016 United States Army Medical Research and Materiel Command initiates a phase I trial in Viral haemorrhagic fevers (Prevention) in USA (IM) (NCT02776761)